Monoclonal Antibodies in Patients with Osteoporosis and Renal Insufficiency: An Updated Systematic Review and Meta-analysis

Overview

Journal Osteoporos Sarcopenia

Date 2024 Jul 22

PMID 39035224

Authors

Maria L R Defante

Victoria Alzogaray

Davi Said Goncalves Celso

Lucas Antonio Torres

Mayara Bearse

Ana Claudia Frota Machado de Melo Lopes

Affiliations

Soon will be listed here.

Abstract

Objectives: There are challenges for the treatment of osteoporosis in patients with kidney failure and monoclonal antibodies (MAb) might be a suitable therapy. However, the efficacy and safety of MAb among patients with osteoporosis and renal insufficiency remains unclear.

Methods: We systematically searched PubMed, Embase, and Cochrane Central for studies evaluating the efficacy and safety of the use of MAb in patients with osteoporosis and renal insufficiency. We pooled risk ratios (RR) and 95% confidence intervals (CI) for binary outcomes. Mean difference (MD) was used for continuous outcomes.

Results: We included 5 studies with 33,550 patients. MAb therapy decreased the risk of vertebral fractures (RR 0.32; 95% CI 0.26-0.40; P < 0.01) when compared to placebo and no statistical difference was found when comparing to bisphosphonate (RR 0.71; 95% CI 0.49-1.03; P = 0.07). MAb therapy also decreased the risk of nonvertebral fractures (RR 0.79; 95% CI 0.69-0.91; P = 0.0009). Lumbar spine bone mineral density (BMD) was higher in the MAb therapy when compared to both placebo (MD 10.90; 95% CI 8.00-13.80; P < 0.01) and bisphosphonate (MD 7.66; 95% CI 6.19-9.14; P < 0.01). There was no statistically significant difference in the change of estimated glomerular filtration rate and in the incidence of hypocalcemia and serious adverse events between groups.

Conclusions: There were reductions in both vertebral and nonvertebral fracture risks, alongside improvements in BMD among patients with renal insufficiency treated with MAb.

References

LeBoff M, Greenspan S, Insogna K, Lewiecki E, Saag K, Singer A . The clinician's guide to prevention and treatment of osteoporosis. Osteoporos Int. 2022; 33(10):2049-2102. PMC: 9546973. DOI: 10.1007/s00198-021-05900-y. View

Jamal S, Ljunggren O, Stehman-Breen C, Cummings S, McClung M, Goemaere S . Effects of denosumab on fracture and bone mineral density by level of kidney function. J Bone Miner Res. 2011; 26(8):1829-35. DOI: 10.1002/jbmr.403. View

Aspray T, Hill T . Osteoporosis and the Ageing Skeleton. Subcell Biochem. 2019; 91:453-476. DOI: 10.1007/978-981-13-3681-2_16. View

Hallan S, Ritz E, Lydersen S, Romundstad S, Kvenild K, Orth S . Combining GFR and albuminuria to classify CKD improves prediction of ESRD. J Am Soc Nephrol. 2009; 20(5):1069-77. PMC: 2678033. DOI: 10.1681/ASN.2008070730. View

Sterne J, Savovic J, Page M, Elbers R, Blencowe N, Boutron I . RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019; 366:l4898. DOI: 10.1136/bmj.l4898. View

Chen C, Lo W, Hu P, Chan H, Shen W, Wu M . Efficacy of Osteoporosis Medications for Patients With Chronic Kidney Disease: An Updated Systematic Review and Network Meta-Analysis. Front Pharmacol. 2022; 13:822178. PMC: 8873386. DOI: 10.3389/fphar.2022.822178. View

Singh S, Dutta S, Khasbage S, Kumar T, Sachin J, Sharma J . A systematic review and meta-analysis of efficacy and safety of Romosozumab in postmenopausal osteoporosis. Osteoporos Int. 2021; 33(1):1-12. PMC: 9003152. DOI: 10.1007/s00198-021-06095-y. View

Ryman J, Meibohm B . Pharmacokinetics of Monoclonal Antibodies. CPT Pharmacometrics Syst Pharmacol. 2017; 6(9):576-588. PMC: 5613179. DOI: 10.1002/psp4.12224. View

Coughlan T, Dockery F . Osteoporosis and fracture risk in older people. Clin Med (Lond). 2014; 14(2):187-91. PMC: 4953292. DOI: 10.7861/clinmedicine.14-2-187. View

10.

Tu K, Lie J, Wan C, Cameron M, Austel A, Nguyen J . Osteoporosis: A Review of Treatment Options. P T. 2018; 43(2):92-104. PMC: 5768298. View

11.

Chen H, Hsu C, Lee Y, Fu C, Wang S, Huang C . Comparative Adverse Kidney Outcomes in Women Receiving Raloxifene and Denosumab in a Real-World Setting. Biomedicines. 2022; 10(7). PMC: 9313089. DOI: 10.3390/biomedicines10071494. View

12.

Miller P, Adachi J, Albergaria B, Cheung A, Chines A, Gielen E . Efficacy and Safety of Romosozumab Among Postmenopausal Women With Osteoporosis and Mild-to-Moderate Chronic Kidney Disease. J Bone Miner Res. 2022; 37(8):1437-1445. PMC: 9544335. DOI: 10.1002/jbmr.4563. View

13.

Luo D, Wan X, Liu J, Tong T . Optimally estimating the sample mean from the sample size, median, mid-range, and/or mid-quartile range. Stat Methods Med Res. 2016; 27(6):1785-1805. DOI: 10.1177/0962280216669183. View

14.

Iseri K, Iyoda M, Watanabe M, Matsumoto K, Sanada D, Inoue T . The effects of denosumab and alendronate on glucocorticoid-induced osteoporosis in patients with glomerular disease: A randomized, controlled trial. PLoS One. 2018; 13(3):e0193846. PMC: 5854344. DOI: 10.1371/journal.pone.0193846. View

15.

Page M, McKenzie J, Bossuyt P, Boutron I, Hoffmann T, Mulrow C . The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021; 372:n71. PMC: 8005924. DOI: 10.1136/bmj.n71. View

16.

Leng Y, Yu X, Yang Y, Xia Y . Efficacy and safety of medications for osteoporosis in kidney transplant recipients or patients with chronic kidney disease: A meta-analysis. J Investig Med. 2023; 71(7):760-772. DOI: 10.1177/10815589231184215. View

17.

Wilson L, Rebholz C, Jirru E, Liu M, Zhang A, Gayleard J . Benefits and Harms of Osteoporosis Medications in Patients With Chronic Kidney Disease: A Systematic Review and Meta-analysis. Ann Intern Med. 2017; 166(9):649-658. DOI: 10.7326/M16-2752. View

18.

Cummings S, San Martin J, McClung M, Siris E, Eastell R, Reid I . Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med. 2009; 361(8):756-65. DOI: 10.1056/NEJMoa0809493. View

19.

Hsu T, Hsu C, Wang S, Huang C, Li L . Comparison of the Effects of Denosumab and Alendronate on Cardiovascular and Renal Outcomes in Osteoporotic Patients. J Clin Med. 2019; 8(7). PMC: 6678904. DOI: 10.3390/jcm8070932. View

20.

Sterne J, Hernan M, Reeves B, Savovic J, Berkman N, Viswanathan M . ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016; 355:i4919. PMC: 5062054. DOI: 10.1136/bmj.i4919. View